Reset

Reset 10 mg Injection can be administered intravenously (IV) or intramuscularly (IM). For IV administration, inject slowly over at least 1-2 minutes to avoid transient but intense feelings of anxiety and restlessness.

Reset acts primarily as a dopamine D2 receptor antagonist, both centrally in the chemoreceptor trigger zone (CTZ) and peripherally in the gastrointestinal tract. It also has weak serotonin 5-HT3 receptor antagonist and 5-HT4 receptor agonist properties, which contribute to its prokinetic effect by increasing acetylcholine release in the enteric nervous system, thereby enhancing gastric emptying and intestinal transit.

• Hypersensitivity to the active substance or any excipients.
• Gastrointestinal hemorrhage, mechanical obstruction, or perforation.
• Patients with pheochromocytoma, due to the risk of hypertensive crisis.
• Patients with epilepsy, as it may increase seizure frequency.
• Patients with a history of tardive dyskinesia from neuroleptics or metoclopramide.
• Use in children less than 1 year of age due to increased risk of extrapyramidal disorders.

Store below 30°C. Protect from light and moisture. Do not freeze. Keep out of reach of children.

Symptoms of overdose may include drowsiness, disorientation, extrapyramidal reactions (e.g., muscle spasms, involuntary movements), and cardiovascular effects such as bradycardia. Management is primarily supportive and symptomatic. Anticholinergic drugs or benzodiazepines may be used to control extrapyramidal symptoms. Monitor vital signs and provide general supportive care.

Reset should be used during pregnancy only if clearly needed and the potential benefits outweigh the potential risks to the fetus. It is excreted into breast milk and may cause adverse effects in the breastfed infant; therefore, use is generally not recommended during lactation or a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

• Hypersensitivity to the active substance or any excipients.
• Gastrointestinal hemorrhage, mechanical obstruction, or perforation.
• Patients with pheochromocytoma, due to the risk of hypertensive crisis.
• Patients with epilepsy, as it may increase seizure frequency.
• Patients with a history of tardive dyskinesia from neuroleptics or metoclopramide.
• Use in children less than 1 year of age due to increased risk of extrapyramidal disorders.

Store below 30°C. Protect from light and moisture. Do not freeze. Keep out of reach of children.

Symptoms of overdose may include drowsiness, disorientation, extrapyramidal reactions (e.g., muscle spasms, involuntary movements), and cardiovascular effects such as bradycardia. Management is primarily supportive and symptomatic. Anticholinergic drugs or benzodiazepines may be used to control extrapyramidal symptoms. Monitor vital signs and provide general supportive care.

Reset should be used during pregnancy only if clearly needed and the potential benefits outweigh the potential risks to the fetus. It is excreted into breast milk and may cause adverse effects in the breastfed infant; therefore, use is generally not recommended during lactation or a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.